Cibenzoline S-isomer

CT-G20 is the S-isomer of cibenzoline, a chemically synthesized small molecule drug in clinical development for the treatment of hypertrophic cardiomyopathy (HCM), specifically obstructive HCM. It is being developed by Celltrion and its subsidiary Celltrion Pharma. The precise mechanism of action has not been fully defined in public sources, but as an S-isomer of cibenzoline, it is presumed to act as a negative inotropic agent that modulates cardiac contractility—potentially through effects on cardiac ion channels or sarcomere function. The drug has undergone Phase 1 clinical trials to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in subjects with obstructive hypertrophic cardiomyopathy[1][3][7].

Other names

CT-G20CT-G-20CT-G 20S-cibenzoline